Dr. Becerra on Ribociclib/Letrozole in ER+/HER2- Breast Cancer

Carlos Becerra, MD
Published: Wednesday, Jul 20, 2016


Carlos Becerra, MD, physician, Texas Oncology, discusses a study examining the combination of ribociclib and letrozole in patients with ER-positive, HER2-negative advanced breast cancer.

To enroll on the trial, patients must have progressed on estrogen receptor inhibitors, Becerra explains. Patients were treated with the combination to determine whether treatment with the CDK 4/6 inhibitor would prevent resistance to letrozole.

Results showed that the combination demonstrated clinical activity as well as an acceptable safety profile in patients, with an overall response rate of 39%.

Carlos Becerra, MD, physician, Texas Oncology, discusses a study examining the combination of ribociclib and letrozole in patients with ER-positive, HER2-negative advanced breast cancer.

To enroll on the trial, patients must have progressed on estrogen receptor inhibitors, Becerra explains. Patients were treated with the combination to determine whether treatment with the CDK 4/6 inhibitor would prevent resistance to letrozole.

Results showed that the combination demonstrated clinical activity as well as an acceptable safety profile in patients, with an overall response rate of 39%.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x